Bhansali, Rahul S
Mayo Clinic
Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Citations 2
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma
Wang, Yucai , Hwang, Steven R. , Villa, Diego , Kugathasan, Laveniya , Kumar, Anita , Joseph, Ashlee , Brooks, Taylor , Hill, Brian T. , Bond, David A. , Maddocks, Kami J. , Nizamuddin, Imran , Danilov, Alexey V. , Argao, Christine, Ruan, Jia , Khan, Nazneen B., Ouchveridze, Evguenia, Mou, Eric , Pongas, Georgios , Lossos, Izidore S. , Harris, Zoey I., Young, Philip, Greenwell, Irl Brian , Gerber, Drew G. , Wang, Michael , Narkhede, Mayur , Stack, Anthony , Messmer, Marcus , Moyo, Tamara K. , Anna, Jacob, Stanisic, Alexander , Cohen, Jonathon B. , Hwang, Steven R , Villa, Diego , Kumar, Anita , Joseph, Ashlee , Brooks, Taylor R , Bond, David A , Kahl, Brad S , Ryan, Christine E , Grover, Natalie S , Tun, Aung M , Mou, Eric , Lossos, Izidore S , Moustafa, Muhamad Alhaj , Pophali, Priyanka , Gerber, Drew , Jain, Preetesh , Wang, Michael L , Narkhede, Mayur S , Mehta, Amitkumar , Stack, Anthony C , Bhansali, Rahul S , Barta, Stefan K , Ghosh, Nilanjan , Kamdar, Manali , Stanisic, Alexander V , Karmali, Reem , Maurer, Matthew , Cerhan, James R , Cohen, Jonathon B , Wang, Yucai , Larson, Melissa C. , Kahl, Brad S. , Ryan, Christine E. , Merryman, Reid W. , Grover, Natalie S. , Ouchveridze, Evguenia, Tun, Aung M. , Ayyappan, Sabarish Ram , Muñoz, Javier , Portell, Craig A. , Baidoun, Firas , Moustafa, Muhamad Alhaj , Reagan, Patrick Michael , Banaszak, Lauren Gabriele , Pophali, Priyanka A. , Velayati, Arash , Jain, Preetesh , Mehta, Amitkumar , Bhansali, Rahul S. , Kamdar, Manali , Anna, Jacob, Karmali, Reem , Maurer, Matthew J. , Cerhan, James R. , Martin, Peter
Blood Advances | December 11, 2025 | Volume: 10 | Issue: 4 | Pages: 1372-1380
10.1182/bloodadvances.2025018527
Abstract The benefit of rituximab maintenance after first-line (1L) bendamustine-rituximab (BR) in patients with mantle cell lymphoma (MCL) remains uncertain, with inconsistent results from the phase 2 MAINTAIN trial and several retrospective studies. We conducted a large retrospective study at 27 US and Canadian academic centers to examine the benefit of rituximab maintenance after BR. A total of 911 patients received 1L BR between 2010 and 2020, and 703 had an objective response and no evidence of disease progression at the 3-month post-BR landmark. Among those, 394 (56%) received rituximab maintenance and 309 (44%) did not, with largely similar baseline patient and disease characteristics. In the landmark analysis, rituximab maintenance was associated with improved event-free survival (EFS; median, 49.9 vs 29.7 months; P< .001) as well as overall survival (OS; median, 109.5 vs 74.2 months; P< .001). The EFS and OS benefits were observed across most of the subgroups. EFS and OS differences were statistically significant in those who achieved a complete response to 1L BR (n = 590; median EFS, 62.7 vs 31.1 months [P< .001]; median OS, 136.1 vs 75.3 months [P< .001]), but the analysis among those who achieved a partial response to 1L BR was limited by the small sample size. These results provide additional evidence for the survival benefit of rituximab maintenance after BR in MCL and support its use in clinical trial design and routine practice.
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas
Bhansali, Rahul S. , Ellin, Fredrik , Relander, Thomas, Cao, Miao , Li, Wenrui , Long, Qi , Ganesan, Nivetha , Stuver, Robert , Wudhikarn, Kitsada, Sokol, Lubomir, Duan, Frank, Pullarkat, Priyanka, Mehta–Shah, Neha , Ruiz, Miguel , Brammer, Jonathan E. , Prakash, Rishab, Iyer, Swaminathan P. , Major, Ajay , Smith, Sonali M. , Goldin, Caroline, Haverkos, Bradley M. , Zhuang, Tony , Allen, Pamela B. , Toama, Wael , Janakiram, Murali , Brooks, Taylor , Jagadeesh, Deepa, Hariharan, Nisha , Goodman, Aaron M. , Hartman, Gabrielle, Fayyaz, Fatima , Gerson, James N. , Svoboda, Jakub , Long, Qi , Wudhikarn, Kitsada , Hwang, Steven R , Bennani, N Nora , Saeed, Hayder , Porcu, Pierluigi , Mehta-Shah, Neha , Zain, Jasmine , Olszewski, Adam J , Smith, Sonali M , Haverkos, Bradley M , Hu, Bei , Zhuang, Tony Z , Allen, Pamela Blair , Toama, Wael , Brooks, Taylor R , Ghione, Paola , Fayyaz, Fatima , Rhodes, Joanna , Chong, Elise A , Barta, Stefan K , Major, Ajay , Janakiram, Murali , Bhansali, Rahul S , Stuver, Robert , Horwitz, Steven M. , Hwang, Steven R. , Bennani, N. Nora , Chavez, Julio C , Olszewski, Adam J. , Riedell, Peter A. , Hu, Bei , Jagadeesh, Deepa , Hariharan, Nisha, Ghione, Paola , Rhodes, Joanna , Chong, Elise A. , Landsburg, Daniel J. , Nasta, Sunita , Schuster, Stephen J. , Jerkeman, Mats
Blood Advances | May 13, 2024 | Volume: 8 | Issue: 13 | Pages: 3507-3518
10.1182/bloodadvances.2024012800
Abstract Little is known about risk factors for central nervous system (CNS) relapse in mature T-cell and natural killer cell neoplasms (MTNKNs). We aimed to describe the clinical epidemiology of CNS relapse in patients with MTNKN and developed the CNS relapse In T-cell lymphoma Index (CITI) to predict patients at the highest risk of CNS relapse. We reviewed data from 135 patients with MTNKN and CNS relapse from 19 North American institutions. After exclusion of leukemic and most cutaneous forms of MTNKNs, patients were pooled with non-CNS relapse control patients from a single institution to create a CNS relapse–enriched training set. Using a complete case analysis (n = 182), including 91 with CNS relapse, we applied a least absolute shrinkage and selection operator Cox regression model to select weighted clinicopathologic variables for the CITI score, which we validated in an external cohort from the Swedish Lymphoma Registry (n = 566). CNS relapse was most frequently observed in patients with peripheral T-cell lymphoma, not otherwise specified (25%). Median time to CNS relapse and median overall survival after CNS relapse were 8.0 and 4.7 months, respectively. We calculated unique CITI risk scores for individual training set patients and stratified them into risk terciles. Validation set patients with low-risk (n = 158) and high-risk (n = 188) CITI scores had a 10-year cumulative risk of CNS relapse of 2.2% and 13.4%, respectively (hazard ratio, 5.24; 95% confidence interval, 1.50-18.26; P = .018). We developed an open-access web-based CITI calculator (https://redcap.link/citicalc) to provide an easy tool for clinical practice. The CITI score is a validated model to predict patients with MTNKN at the highest risk of developing CNS relapse.